Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NTRK1 | P04629 | 3/20 | 0.49 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | STAT1 | P42224 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | SPR | P35270 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.44 |
| ▸ | POLB | P06746 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21774132 | 0.86 | MAPT (0.42) | NTRK1MAPTTP53LMNASTAT1 | |
| SCHEMBL21774330 | 0.85 | KMT2A (0.59) | NTRK1MAPTTP53LMNASTAT1 | |
| SCHEMBL21774128 | 0.85 | MAPT (0.44) | NTRK1MAPTTP53LMNASTAT1 | |
| SCHEMBL21774344 | 0.84 | MAPT (0.53) | MAPTTP53LMNASTAT1TDP1 | |
| SCHEMBL21775658 | 0.83 | KMT2A (0.50) | MAPTTP53LMNASTAT1TDP1 | |
| SCHEMBL21774298 | 0.82 | MAPT (0.57) | MAPTTP53LMNASTAT1TDP1 | |
| SCHEMBL21774127 | 0.82 | MAPT (0.52) | MAPTTP53LMNASTAT1TDP1 | |
| SCHEMBL21774133 | 0.82 | MAPT (0.49) | NTRK1MAPTLMNASTAT1TDP1 | |
| SCHEMBL21774381 | 0.81 | KMT2A (0.51) | NTRK1MAPTTP53LMNASTAT1 | |
| SCHEMBL21774299 | 0.80 | ALDH1A1 (0.49) | NTRK1MAPTTP53LMNASTAT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11692004-B2 | Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof | JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| US-11692004-B2 | Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof | JIANGSU VANGUARD PHARMACEUTICAL CO., LTD. (CN) | 2023-07-04 | — | — | US | disclosed |
| WO-2020038279-A1 | SUBSTITUTED PYRAZOLE COMPOUND, AND PREPARATION METHOD, PHARMACEUTICAL COMPOSITION, AND USE THEREOF | 天津谷堆生物医药科技有限公司 | 2020-02-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11692004-B2 | Substituted pyrazole compound, preparation method therefor, pharmaceutical composition and medical use thereof | FARS2, GOT2, HADHB | NTRK1 2744/4885MAPT 856/4885TP53 695/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.